dc.contributor.author | Joranger, Pål | |
dc.contributor.author | Nesbakken, Arild | |
dc.contributor.author | Sorbye, Halfdan | |
dc.contributor.author | Hoff, Geir | |
dc.contributor.author | Oshaug, Arne | |
dc.contributor.author | Aas, Eline | |
dc.date.accessioned | 2020-01-28T13:11:36Z | |
dc.date.accessioned | 2020-04-17T22:05:36Z | |
dc.date.available | 2020-01-28T13:11:36Z | |
dc.date.available | 2020-04-17T22:05:36Z | |
dc.date.issued | 2019-11-09 | |
dc.identifier.citation | Joranger P, Nesbakken A, Sorbye H, Hoff G, Oshaug A, Aas E. Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. European Journal of Health Economics. 2019:1-14 | en |
dc.identifier.issn | 1618-7598 | |
dc.identifier.issn | 1618-7598 | |
dc.identifier.issn | 1618-7601 | |
dc.identifier.uri | https://hdl.handle.net/10642/8453 | |
dc.description.abstract | New and emerging advances in colorectal cancer (CRC) treatment combined with limited healthcare resources highlight the need for detailed decision-analytic models to evaluate costs, survival and quality-adjusted life years. The objectives of this article were to estimate the expected lifetime treatment cost of CRC for an average 70-year-old patient and to test the applicability and flexibility of a model in predicting survival and costs of changing treatment scenarios. The analyses were based on a validated semi-Markov model using data from a Norwegian observational study (2049 CRC patients) to estimate transition probabilities and the proportion resected. In addition, inputs from the Norwegian Patient Registry, guidelines, literature, and expert opinions were used to estimate resource use. We found that the expected lifetime treatment cost for a 70-year-old CRC patient was €47,300 (CRC stage I €26,630, II €38,130, III €56,800, and IV €69,890). Altered use of palliative chemotherapy would increase the costs by up to 29%. A 5% point reduction in recurrence rate for stages I-III would reduce the costs by 5.3% and increase overall survival by 8.2 months. Given the Norwegian willingness to pay threshold per QALY gained, society's willingness to pay for interventions that could result in such a reduction was on average €28,540 per CRC patient. The life years gained by CRC treatment were 6.05 years. The overall CRC treatment costs appear to be low compared to the health gain, and the use of palliative chemotherapy can have a major impact on cost. The model was found to be flexible and applicable for estimating the cost and survival of several CRC treatment scenarios. | en |
dc.description.sponsorship | We acknowledge the Department of Health, Nutrition and Management (HEL), The Faculty of Health Sciences, and Oslo and Akershus University College of Applied Sciences for funding Paal Joranger’s doctorate. | en |
dc.language.iso | en | en |
dc.publisher | Springer Verlag | en |
dc.relation.ispartofseries | European Journal of Health Economics; | |
dc.rights | This is a post-peer-review, pre-copyedit version of an article published in European Journal of Health Economics. The final authenticated version is available online at:
https://dx.doi.org/10.1007/s10198-019-01130-6 | en |
dc.subject | Colorectal cancer | en |
dc.subject | Markov models | en |
dc.subject | Costs | en |
dc.subject | Surgeries | en |
dc.subject | Chemotherapy | en |
dc.subject | Analyse innovations | en |
dc.title | Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach | en |
dc.type | Journal article | en |
dc.type | Peer reviewed | en |
dc.date.updated | 2020-01-28T13:11:36Z | |
dc.description.version | acceptedVersion | en |
dc.identifier.doi | https://dx.doi.org/10.1007/s10198-019-01130-6 | |
dc.identifier.cristin | 1746591 | |
dc.source.journal | European Journal of Health Economics | |